Increased reports of measles in the Metropolitan City of Milan, northern Italy, September 2023 to March 2024

Gori, Maria; Fappani, Clara; Bianchi, Silvia; Senatore, Sabrina; Colzani, Daniela; Pasutto, Priscilla; Baggieri, Melissa; Gioacchini, Silvia; Marchi, Antonella; Bucci, Paola; D’Ugo, Emilio; Faccini, Marino; Cereda, Danilo; Vezzosi, Luigi; Tanzi, Elisabetta; Magurano, Fabio; Amendola, Antonella

doi:10.2807/1560-7917.es.2024.29.16.2400201

Eurosurveillance

2024

DOI: 10.2807/1560-7917.es.2024.29.16.2400201

|View full text |Cite

Increased reports of measles in the Metropolitan City of Milan, northern Italy, September 2023 to March 2024

Maria Gori,

Clara Fappani,

Silvia Bianchi

et al.

Abstract: Since late 2023, the Metropolitan City of Milan and surrounding areas (northern Italy) have been experiencing a resurgence of measles, with most cases detected starting from January 2024. During this brief period, we observed measles in travellers from endemic areas, participants in international events, vaccinees and healthcare workers. Indigenous cases have also been identified. Even though we have not yet identified large and disruptive outbreaks, strengthening surveillance and vaccination activities is piv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Differential diagnosis on measles and rubella discarded cases highlights a sharp increase in parvovirus B19 infections in Milan, Northern Italy, in the first months of 2024

Fappani,

Gori,

Bianchi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

In line with European trends, since 2023 Lombardy (Northern Italy) is experiencing a resurgence of measles and an increased number of reported cases of fever and rash. Measles discarded cases observed in our region within the context of measles and rubella surveillance from the first few months of 2024 (N = 30) were investigated for parvovirus B19 (B19V) and other rash‐associated viruses. Thirteen cases tested positive for B19V DNA, representing a significant increase from previous years (on average 3 cases per year, p < 0.001) and ~40% of all B19V DNA‐positive patients we detected since 2017. In 2024, B19V DNA‐positive subjects spanned all ages, and the virus was predominant among adolescents and adults (84.6%). Two B19V infected patients were hospitalised, and likely cross‐reacting anti‐measles virus IgM were found in both. Our data align with the recent reports from the ECDC and various European countries, which are experiencing a surge in B19V infections, and underline the importance of comprehensive measles and rubella surveillance systems that can adapt to changing epidemiological trends.

show abstract

Differential diagnosis on measles and rubella discarded cases highlights a sharp increase in parvovirus B19 infections in Milan, Northern Italy, in the first months of 2024

Fappani,

Gori,

Bianchi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Estimating the proportion of health care workers susceptible to measles infection in a large university hospital in Milan, Italy, 2019−2023

Rizzo,

Mendola,

Salari

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Global burden associated with rare infectious diseases of poverty in 2021: findings from the Global Burden of Disease Study 2021

Bao,

Li,

Zhou

et al. 2024

Infect Dis Poverty

View full text Add to dashboard Cite

Background Rare infectious diseases of poverty (rIDPs) involve more than hundreds of tropical diseases, which dominantly affect people living in impoverished and marginalized regions and fail to be prioritized in the global health agenda. The neglect of rIDPs could impede the progress toward sustainable development. This study aimed to estimate the disease burden of rIDPs in 2021, which would be pivotal for setting intervention priorities and mobilizing resources globally. Methods Leveraging data from the Global Burden of Disease Study 2021, the study reported both numbers and age-standardized rates of prevalence, mortality, disability-adjusted life-years (DALYs), years lived with disability, and years of life lost of rIDPs with corresponding 95% uncertainty intervals (UIs) at global, regional, and national levels. The temporal trends between 1990 and 2021 were assessed by the joinpoint regression analysis. A Bayesian age-period-cohort model was used to project the disease burden for 2050. Results In 2021, there were 103.76 million (95% UI: 102.13, 105.44 million) global population suffered from rIDPs with an age-standardized DALY rate of 58.44 per 100,000 population (95% UI: 42.92, 77.26 per 100,000 population). From 1990 to 2021, the age-standardized DALY rates showed an average annual percentage change of − 0.16% (95% confidence interval: − 0.22, − 0.11%). Higher age-standardized DALY rates were dominated in sub-Saharan Africa (126.35 per 100,000 population, 95% UI: 91.04, 161.73 per 100,000 population), South Asia (80.80 per 100,000 population, 95% UI: 57.31, 114.10 per 100,000 population), and countries with a low socio-demographic index. There was age heterogeneity in the DALY rates of rIDPs, with the population aged under 15 years being the most predominant. Females aged 15–49 years had four-times higher age-standardized DALY rates of rIDPs than males in the same age. The projections indicated a slight reduction in the disease burden of rIDPs by 2050. Conclusions There has been a slight reduction in the disease burden of rIDPs over the past three decades. Given that rIDPs mainly affect populations in impoverished regions, targeted health strategies and resource allocation are in great demand for these populations to further control rIDPs and end poverty in all its forms everywhere. Graphical Abstract

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Increased reports of measles in the Metropolitan City of Milan, northern Italy, September 2023 to March 2024

Cited by 3 publications

References 8 publications

Differential diagnosis on measles and rubella discarded cases highlights a sharp increase in parvovirus B19 infections in Milan, Northern Italy, in the first months of 2024

Differential diagnosis on measles and rubella discarded cases highlights a sharp increase in parvovirus B19 infections in Milan, Northern Italy, in the first months of 2024

Estimating the proportion of health care workers susceptible to measles infection in a large university hospital in Milan, Italy, 2019−2023

Global burden associated with rare infectious diseases of poverty in 2021: findings from the Global Burden of Disease Study 2021

Contact Info

Product

Resources

About